Ascentage Pharma (6855.HK), a China-based, global biopharmaceutical company, announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, to enter a first-in-human (FIH) study that will evaluate the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumours or hematologic malignancies.
This multicentre, open-label Phase one study is aimed at evaluating the safety and tolerability, and determining the dose-limiting toxicity, maximum tolerated dose, and recommended Phase II dose (RP2D) of orally administered APG-5918. The Principal Investigator of this multicentric clinical trial is Prof Joseph Paul Eder, clinical director of the Early Drug Development Program at Yale Cancer Center.
APG-5918 is an orally active, potent, selective, small-molecule EED inhibitor with high binding affinity. It was discovered and developed by Ascentage Pharma. It selectively binds to the EED protein.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT